CompletedPhase 4

ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)

Italy62 participantsStarted 2005-03-01

Plain-language summary

Comparison of clinical efficacy and safety of levocetirizine in PER continuous versus on demand, measured by evolution of individual symptom scores during 6 months.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinical history of Persistent allergic Rhinitis (PER) requiring treatment known at least since 2 years. * Positive skin prick test (wheal \> 3 mm larger than the diluent control) or Radio Allergo Sorbent Assay (RAST) (\>= 3.5 IU/ml) to House Dust Mite (HDM) and Parietaria (less than 1 year). * Minimum mean Total 4 Symptom Score (T4SS) of 6 over baseline period. Exclusion Criteria: * Subjects currently treated by specific parietaria pollen immunotherapy * Subjects suffering from non-allergic asthma * Chronic use of inhaled steroids and/or long acting β2 agonists; and/or corticosteroids dependent asthma (severe asthma) * Atopic dermatitis or urticaria requiring antihistamine treatment or the administration of oral or topical corticosteroids

What they're measuring

Mean Weekly Total 4 Symptom Score (T4SS) During the Treatment Period

Timeframe: During the treatment period until week 24

Trial details

NCT IDNCT00160680

SponsorUCB S.A. - Pharma Sector

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2006-06-01

Results submitted2017-10-10

View on ClinicalTrials.gov More Rhinitis, Allergic, Perennial trials